



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: 28th October, 2024

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 531569

Sub: Press Release on Unaudited Financial Results for the quarter and half year ended September 30, 2024.

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on Unaudited Financial Results for the quarter and half year ended September 30, 2024.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam
Company Secretary Cum Compliance Officer

Press Release

Sanjivani Paranteral Limited reported a strong performance for the quarter ended 30th September 2024

Mumbai, 28, October 2024: Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said, "Sanjivani Paranteral Ltd. has achieved a sturdy growth trajectory this quarter, reaffirming our commitment to quality and innovation across key therapeutic areas. Our operational efficiencies continue to strengthen, even amidst a dynamic market landscape, highlighting our dedication to sustainable progress. We are excited about the strides we're making to expand our R&D capabilities and extend our reach in essential markets like the CIS, Middle East, and Latin America. Each step we take today positions us to deliver greater value for our customers, partners, and shareholders, supporting our long-term vision in the global pharmaceutical industry."

Financial Summary:

Q2 FY25:

- Revenue from operation grew 29.5% YoY to INR 181.3 mn.
- EBITDA margin stood at 17.9% (up 171bps YoY).
- Profit After Tax (PAT) margins stood at 12.4% (up 34bps YoY).

Particulars (Rs. in mn.)	Q2FY25	Q2FY24	Q1FY24	H1FY25	H1FY24	FY24
Total Income	185.2	141.5	165.2	350.4	267.9	549.3
Gross Profit	76.2	51.9	62.6	138.8	112.4	264.4
Gross Margin (%)	42.0%	37.1%	38.1%	40.2%	42.3%	48.6%
EBITDA incl. other income	32.4	22.6	24.2	56.6	43.4	87.6
EBITDA Margin (%)	17.9%	16.2%	14.7%	16.4%	16.3%	16.1%
PBT	29.2	19.9	22.7	51.9	37.9	75.7
PBT Margin %	15.7%	14.0%	13.8%	14.8%	14.1%	13.8%
PAT	23.0	17.1	17.1	40.1	32.6	61.7
PAT Margin (%)	12.4%	12.1%	10.4%	11.4%	12.2%	11.2%
EPS (in INR)	1.96	1.71	1.47	3.43	3.26	5.28

Segment-wise Performance:

- **Injectables:** Revenue grew 21.9% YoY to Rs. 90.7mn.

- **Oral:** Revenue grew 10.3% YoY to INR 77.3mn.
- **Nutraceuticals:** Revenue stood at INR 13.4mn.

Market-Wise Performance:

- Exports (incl. Exports incentives) constitute 81.3% of total revenue while domestic constitutes 18.8%.
- Core markets of CIS (incl Russia), Middle East & Africa and Latin America, accounted for 81.2% to INR 147.4mn.

H1 FY25:

- Revenue from operation grew 30.0% YoY to INR 345.7 mn.
- EBITDA margin stood at 16.4%.
- Profit After Tax (PAT) grew 23.2% YoY to INR 40.1 mn. PAT margin stood at 11.4%.

Segment-wise Performance:

- **Injectables:** Revenue de-grew 1.9% YoY to Rs. 152.5mn.
- **Oral:** Revenue grew 45.0% YoY to INR 175.9mn.
- **Nutraceuticals:** Revenue stood at INR 17.3mn.

Market-Wise Performance:

- Core markets of CIS (including Russia), and Latin America, accounted for 84.6% of H1FY25 revenue to Rs 292.5 mn.

Pritesh Jain

Sanjivani Paranteral
Chief Financial Officer
pritesh.jain@sanjivani.co.in

Vijay Gyanchandani / Jill Chandrani

S-ancial Technologies
vijay@s-ancial.com / jill@s-ancial.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.